The Genome Sensor™ is powered by Cardea Field Effect Biosensing (FEB) and CRISPR-Chip™ technology to provide researchers and scientists with quick identification of their chosen genetic mutations of interest.
Field Effect Biosensing™
FEB is a label-free nano-electrical technology for measuring biomolecular interactions. Measuring the current across a graphene biosensor surface, any interaction or binding on the surface causes a change in conductance that a monitoring system can identify and translate to be interpreted by the user interface. Our patent protected FEB technology was invented by Cardea and we have used the technology to power our Genome Sensor.
By combining thousands of CRISPR-dcas9 molecules with Cardea’s graphene biosensors, our proprietary and patented CRISPR-Chip technology has the power to google genomes for specific sequences of interest. While the opportunities are endless, CRISPR-Chip has successfully proven Genome Sensor’s capabilities to detect genetic mutations such as sickle cell disease and Duchenne muscular dystrophy (DMD).